Ordaos
NEW YORK, New York, United States · Artificial Intelligence, Biotechnology, Health Care · 32 employees
Ordaōs is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods.
Funding history
- Seed — $338K — Apr 2025
- Seed — $3.1M — Sep 2024
- Seed — $500K — Dec 2023
- Seed — $332K — Dec 2023
- Seed — $5.0M — Aug 2022
Recent signals
- Apr 01, 2025: Raised $338K in Seed
- Sep 11, 2024: Raised $3.1M in Seed
- Mar 11, 2024: Acquired Ordaōs completes acquisition of the Carterra®LSA® Platform to optimize its machine-driven drug design system
- Dec 29, 2023: Raised $500K in Seed
- Dec 28, 2023: Raised $332K in Seed
- Aug 25, 2022: Raised $5.0M in Seed
- Jun 15, 2022: Raised $10.7M in Venture - Series Unknown
See plans & pricing → Track Ordaos’s funding, hiring, and signals — with verified contacts — on Fundz.